SNAC and the mechanism of oral peptide absorption — the long version

SNAC and the mechanism of oral peptide absorption — the long version Writing it up because I had to work it out twice and would rather nobody else did.

Question about what the published evidence for this compound actually consists of.

Every summary I can find describes a mechanism and then describes an effect, without ever saying which studies sit between the two. That gap is the thing I want to understand.

Preclinical, human, or neither — I would like to know which, before anything else.

The gastrointestinal tolerability profile of the oral formulation is broadly similar in character to the injectable, which supports the effects being systemic rather than local irritation.

I read the opening post twice before replying, because I had assumed the opposite.

Storage for a small molecule is a different problem from storage for a peptide: generally more robust, generally less temperature-sensitive, and generally more affected by humidity.

One of those cases where knowing the mechanism does not help the decision.

Timing consistency matters more for oral dosing than for weekly injection, because absorption depends on the state of the stomach and the state of the stomach varies through the day.

I would treat that as a working assumption and revisit it.

PIONEER 6 is the cardiovascular outcome trial for oral semaglutide and it enrolled a diabetes population at high cardiovascular risk. Quoting it outside that population is an extrapolation.

The literature is thinner on this than the confidence in the thread implies.

Dose equivalence between oral and injectable formulations is not a simple conversion and no published factor should be used as one. The two were developed and titrated separately.

Coming back to post #5, because the follow-up matters more than the original answer.

Tablet integrity matters more than people expect for a formulation that depends on an absorption enhancer released at a particular place. Splitting or crushing is not a dose adjustment; it is a different product.

Filing this under things that are true until someone shows me otherwise.

That is a cleaner way of putting what I was circling around.

On post #5 — agreed on the reasoning, with one qualification.

Why an oral formulation is a formulation achievement: the molecule is the same but the tablet is novel. Getting a peptide across the gastric epithelium at usable bioavailability is a chemistry problem, not a dose problem.

Flagging that the sources on this are thinner than the confidence in the thread suggests.

Picking up post #9: that is the part I would want checked first.

PIONEER 6 was a cardiovascular safety trial for oral semaglutide, not an efficacy trial. Non-inferiority for safety was demonstrated. The point estimates favoured the drug but the trial was not designed to establish benefit.

The number is defensible. The precision I gave it is not.

Adding a data point of agreement rather than a data point.

Orforglipron is a small molecule rather than a peptide, which changes almost everything about how it is made, stored and analysed. Comparing it to oral semaglutide as though they were the same pharmaceutical problem is a category error.

The general answer and the answer for your case may diverge here.

Taking the oral product with more water than instructed reduces absorption rather than helping it. That is counter-intuitive and it is one of the few dosing instructions in this field with a clear pharmacokinetic basis.

Old habit: I write down the expected answer before I calculate it.

Everything in post #12 holds. The case it does not cover is the one I have.

On variability: the between-person spread in exposure for oral semaglutide is wide enough that two people on the same dose can have quite different plasma concentrations. That is inherent to the absorption route.